select a format

Single User License
USD 250 INR 16030
Site License
USD 500 INR 32060
Corporate User License
USD 750 INR 48090

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH59641D
  • |
  • Pages: 105
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company provides a diversified portfolio of biotechnology and pharmaceutical products. Its marketed product portfolio encompasses indication for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand's clinical development portfolio comprises medications targeted at the treatment of seizure, cancer, diabetes, coma, cardiovascular disease, liver disease, muscle wasting, kidney disease, and others. In partnership with other pharmaceutical companies the company also offers late-stage development, regulatory management and commercialization support. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20

Venture Financing 21

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21

Partnerships 22

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 22

Symphogen Enters Into Agreement With Open Monoclonal Technology 23

Open Monoclonal Expands Agreement with CNA Development 23

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 24

Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 25

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 26

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 27

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 28

WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 29

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 30

Licensing Agreements 31

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 31

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 32

Novartis Enters into Licensing Agreement with Ligand Pharma 33

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 33

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 34

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 35

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 36

TeneoBio Enters into Licensing Agreement with Ligand Pharma 37

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 38

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 38

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 39

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 40

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 40

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 41

RODES Enters into Licensing Agreement with Ligand Pharma 42

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 43

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 43

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 44

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 45

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 46

Sanofi Enters into Licensing Agreement with Ligand Pharma 46

Open Monoclonal Enters into Licensing Agreement with Amgen 47

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 48

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 49

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 50

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 50

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 51

Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 52

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 54

Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 55

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 55

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 57

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 57

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 58

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 59

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 60

Ligand Pharma Enters Into Licencing Agreement With Merck 61

Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 62

Ligand Pharma Enters Into Licensing Agreement With Hospira 63

Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 64

Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 65

Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 66

Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 67

Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 68

Equity Offering 69

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 69

Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 70

Debt Offering 71

Ligand Pharma Prices Private Placement of 0.75% Notes Due 2019 for USD225 Million 71

Acquisition 73

Ligand Pharma to Acquire Open Monoclonal Technology for USD178 Million 73

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 74

Ligand Pharma Acquires CyDex Pharma 75

Ligand Pharmaceuticals Inc-Key Competitors 77

Key Employees 78

Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Recent Developments 81

Financial Announcements 81

May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 81

Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 84

Nov 03, 2016: Ligand Reports Third Quarter 2016 Financial Results 87

Aug 04, 2016: Ligand Reports Second Quarter 2016 Financial Results 90

May 04, 2016: Ligand Reports First Quarter 2016 Financial Results 93

Feb 10, 2016: Ligand Reports Fourth Quarter and Full Year 2015 Financial Results 96

Clinical Trials 99

Feb 27, 2017: Enrollment Completed in Ligand's Phase 2 Trial of LGD-6972 in Type 2 Diabetes 99

Sep 13, 2016: Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes 100

Aug 15, 2016: Results from Phase 1 Trials with Ligand LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism 101

Other Significant Developments 103

Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 103

Appendix 105

Methodology 105

About GlobalData 105

Contact Us 105

Disclaimer 105

List of Figures

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 11

Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19

Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20

Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 22

Symphogen Enters Into Agreement With Open Monoclonal Technology 23

Open Monoclonal Expands Agreement with CNA Development 23

Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 24

Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 25

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26

Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 26

Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 27

Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 28

WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 29

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 30

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 31

Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 32

Novartis Enters into Licensing Agreement with Ligand Pharma 33

Ono Pharma Enters into Licensing Agreement with Ligand Pharma 33

Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 34

Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 35

Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 36

TeneoBio Enters into Licensing Agreement with Ligand Pharma 37

Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 38

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 38

ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 39

Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 40

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 40

XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 41

RODES Enters into Licensing Agreement with Ligand Pharma 42

Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 43

Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 43

ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 44

Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 45

Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 46

Sanofi Enters into Licensing Agreement with Ligand Pharma 46

Open Monoclonal Enters into Licensing Agreement with Amgen 47

HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 48

Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 49

Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 50

Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 50

Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 51

Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 52

Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 54

Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 55

Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 55

Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 57

Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 57

Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 58

MEI Pharma Enters into Licensing Agreement with Ligand Pharma 59

MEI Pharma Enters into Licensing Agreement with CyDex Pharma 60

Ligand Pharma Enters Into Licencing Agreement With Merck 61

Ligand Pharma Enters Into Licensing Agreement With Retrophin For Dual Acting Receptor Antagonist 62

Ligand Pharma Enters Into Licensing Agreement With Hospira 63

Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 64

Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 65

Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 66

Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 67

Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 68

Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 69

Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 70

Ligand Pharma Prices Private Placement of 0.75% Notes Due 2019 for USD225 Million 71

Ligand Pharma to Acquire Open Monoclonal Technology for USD178 Million 73

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 74

Ligand Pharma Acquires CyDex Pharma 75

Ligand Pharmaceuticals Inc, Key Competitors 77

Ligand Pharmaceuticals Inc, Key Employees 78

Ligand Pharmaceuticals Inc, Subsidiaries 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ligand Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com